Advanced NanoTherapies (ANT), based in Santa Clara, California, is developing SirPlux Duo, a dual-drug (paclitaxel and sirolimus) nanoparticle-coated balloon intended for coronary and peripheral vascular interventions. The technology, exclusively licensed from Cleveland Clinic, is a biodegradable, drug-agnostic platform designed to enable controlled cellular uptake and sustained tissue retention. SirPlux Duo has received FDA Breakthrough Device designation and is under clinical evaluation in the ADVANCE-DUO study, supported by a first-in-human 28-patient study with two-year follow-up and an ongoing 30-patient study in Spain. The company plans to scale manufacturing and complete testing packages to support U.S. IDE submissions for coronary indications (in-stent restenosis and small-vessel de novo lesions) and a BTK early feasibility study. Financially, ANT recently closed an oversubscribed Series B round raising more than $31 million to fund regulatory, clinical, and manufacturing milestones.

Total raised

$48M

Funding rounds

4

Latest round

Series B

Latest activity

Jun 2026